Zhang W. Xia W. Lv Z. et al.

Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?.

Cell Physiol Biochem. 41: 755-768

Biological and therapeutic impact of intratumor heterogeneity in cancer evolution.

Cancer Cell. 27: 15-26Aghamir S.M.K. Heshmat R. Ebrahimi M. et al.

Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors.

Epigenet Insights. 13 ()https://doi.org/10.1177/2516865720904052

Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?.

Genome Med. 5: 70

A Case of Cancer in Which Cells Similar to Those in the Tumours Were Seen in the Blood after Death.

Med J Aust. 14: 146-147

Nuclear Acids In Human Blood Plasma.

C R Seances Soc Biol Fil. 142 (): 241-243Anker P. Stroun M. Maurice P.A.

Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system.

Cancer Res. 35: 2375-2382Jahr S. Hentze H. Englisch S. et al.

DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.

Cancer Res. 61: 1659-1665Bronkhorst A.J. Wentzel J.F. Aucamp J. et al.

Characterization of the cell-free DNA released by cultured cancer cells.

Biochim Biophys Acta. 1863: 157-165

Tumor dissemination: an EMT affair.

Cancer Cell. 23: 272-273

Significance of blood vessel leakiness in cancer.

Cancer Res. 62: 5381-5385Cristofanilli M. Budd G.T. Ellis M.J. et al.

Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

N Engl J Med. 351: 781-791Stroun M. Lyautey J. Lederrey C. et al.

About the possible origin and mechanism of circulating DNA apoptosis and active DNA release.

Clin Chim Acta. 313: 139-142Joosse S.A. Gorges T.M. Pantel K.

Biology, detection, and clinical implications of circulating tumor cells.

EMBO Mol Med. 7: 1-11Scholer L.V. Reinert T. Orntoft M.W. et al.

Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer.

Clin Cancer Res. 23: 5437-5445Diehl F. Schmidt K. Choti M.A. et al.

Circulating mutant DNA to assess tumor dynamics.

Nat Med. 14: 985-990Aceto N. Bardia A. Miyamoto D.T. et al.

Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.

Cell. 158: 1110-1122Alix-Panabieres C. Pantel K.

Technologies for detection of circulating tumor cells: facts and vision.

Lab Chip. 14: 57-62Allard W.J. Matera J. Miller M.C. et al.

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.

Clin Cancer Res. 10: 6897-6904Saucedo-Zeni N. Mewes S. Niestroj R. et al.

A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire.

Int J Oncol. 41: 1241-1250Ozkumur E. Shah A.M. Ciciliano J.C. et al.

Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.

Sci Transl Med. 5: 179ra47Xu L. Mao X. Imrali A. et al.

Optimization and evaluation of a novel size based circulating tumor cell isolation system.

PLoS One. 10: e0138032Siravegna G. Marsoni S. Siena S. et al.

Integrating liquid biopsies into the management of cancer.

Nat Rev Clin Oncol. 14: 531-548Postel M. Roosen A. Laurent-Puig P. et al.

Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective.

Expert Rev Mol Diagn. 18: 7-17Shen S.Y. Singhania R. Fehringer G. et al.

Sensitive tumour detection and classification using plasma cell-free DNA methylomes.

Nat Nov. 563: 579-583Siegel R.L. Miller K.D. Fuchs H.E. et al.

Cancer statistics.

CA Cancer J Clin. 72: 7-33Hennigan S.T. Trostel S.Y. Terrigino N.T. et al.

Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer.

JCO Precis Oncol. https://doi.org/10.1200/PO.19.00176de Bono J.S. Scher H.I. Montgomery R.B. et al.

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Clin Cancer Res. 14: 6302-6309Nagaya N. Nagata M. Lu Y. et al.

Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.

PLoS One. 15: e0226219Miyamoto D.T. Lee R.J. Stott S.L. et al.

Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.

Cancer Discovery. 2: 995-1003Armstrong A.J. Halabi S. Luo J. et al.

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.

J Clin Oncol. 37: 1120-1129Scher H.I. Heller G. Molina A. et al.

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.

J Clin Oncol. 33: 1348-1355Heller G. McCormack R. Kheoh T. et al.

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.

J Clin Oncol. 36: 572-580Wyatt A.W. Azad A.A. Volik S.V. et al.

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.

JAMA Oncol. 2: 1598-1606Goodall J. Mateo J. Yuan W. et al.

Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition.

Cancer Discovery. 7: 1006-1017Morris M.J. Molina A. Small E.J. et al.

Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.

J Clin Oncol. 33: 1356-1363Mateo J. Porta N. Bianchini D. et al.

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.

Lancet Oncol. 21: 162-174Lorente D. Olmos D. Mateo J. et al.

Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.

Eur Urol. 70: 985-992Herberts C. Annala M. Sipola J. et al.

Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.

Nature. 608: 199-208

T1 bladder cancer: current considerations for diagnosis and management.

Nat Rev Urol. 16: 23-34Chang S.S. Bochner B.H. Chou R. et al.

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.

J Urol Sep. 198: 552-559Busetto G.M. Ferro M. Del Giudice F. et al.

The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non-muscle-invasive Bladder Cancer.

Clin Genitourin Cancer. 15: e661-e666Gradilone A. Petracca A. Nicolazzo C. et al.

Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer.

BJU Int. 106: 710-715Rink M. Chun F.K. Minner S. et al.

Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer.

BJU Int. 107: 1668-1675Flaig T.W. Wilson S. van Bokhoven A. et al.

Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma.

Urology. 78: 863-867Naoe M. Ogawa Y. Morita J. et al.

Detection of circulating urothelial cancer cells in the blood using the CellSearch System.

Cancer. 109: 1439-1445Birkenkamp-Demtroder K. Nordentoft I. Christensen E. et al.

Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.

Eur Urol. 70: 75-82Christensen E. Birkenkamp-Demtroder K. Nordentoft I. et al.

Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.

Eur Urol. 71: 961-969Christensen E. Birkenkamp-Demtroder K. Sethi H. et al.

Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma.

J Clin Oncol. 37: 1547-1557Agarwal N. Pal S.K. Hahn A.W. et al.

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

Cancer. 124: 2115-2124Motzer R.J. Jonasch E. Agarwal N. et al.

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 20: 71-90Janzen N.K. Kim H.L. Figlin R.A. et al.

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.

Urol Clin North Am. 30: 843-852Bluemke K. Bilkenroth U. Meye A. et al.

Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis.

Cancer Epidemiol Biomarkers Prev. 18: 2190-2194Nel I. Gauler T.C. Bublitz K. et al.

Circulating Tumor Cell Composition in Renal Cell Carcinoma.

PLoS One. 11: e0153018Wan J. Zhu L. Jiang Z. et al.

Monitoring of plasma cell-free DNA in predicting postoperative recurrence of clear cell renal cell carcinoma.

Urol Int. 91: 273-278Skrypkina I. Tsyba L. Onyshchenko K. et al.

Concentration and Methylation of Cell-Free DNA from Blood Plasma as Diagnostic Markers of Renal Cancer.

Dis Markers. 2016: 3693096Yamamoto Y. Uemura M. Fujita M. et al.

Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.

Cancer Sci. 110: 617-628Zill O.A. Banks K.C. Fairclough S.R. et al.

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.

Clin Cancer Res. 24: 3528-3538Hahn A.W. Gill D.M. Maughan B. et al.

Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications.

Oncotarget. 8: 33614-33620Pal S.K. Sonpavde G. Agarwal N. et al.

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.

Eur Urol. 72: 557-564